Enroll in our Anxiety Study
We are investigating the effectiveness of open-label placebo treatments in anxiety sufferers. You can read more about the details of the study here.
Who Can Join
Men and women between age 18 and 75 years old.
Have an anxiety disorder, including: social anxiety disorder (SAD), generalized anxiety disorder (GAD), panic disorder, or agoraphobia.
Must understand study procedure and willing to participate in studies and treatment as assigned.
Participants must be able to give informed consent to the study procedures.
Eligibility Criteria
We aim to enroll 368 participants total in the United States. With a projected dropout rate of 25%, we expect 276 completers. Subjects must be between 18-75 years of age, have an anxiety disorder, and agree to participate in this study.
About the Study
We will examine several secondary outcome measures and exploratory outcomes. Overall Anxiety Severity and Impairment Scale (OASIS) is the secondary measure of anxiety symptoms. To assess satisfaction/acceptability of treatment, we will use the Client Satisfaction Questionnaire (CSQ) and the Reactions to Treatment Questionnaire (RTQ). To assess sleep outcomes, we will use the Pittsburgh Sleep Quality Index (PSQI), The Beck Anxiety Inventory (BAI) is a 21-item self-report inventory designed to measure severity of anxiety symptoms in psychiatric populations. The PROMIS - Emotional Distress scales (ED) will be used to assess emotional distress in the past 7 days, including depressive symptoms, anxiety symptoms, and anger. Other patient-reported measures include the Penn State Worry Questionnaire (PSWQ), the Inventory of Complicated Grief (ICG), and the Health Performance Questionnaire (HPQ). We will also use the Quick Inventory of Depressive Symptomatology, Self-Report, or QIDS-SR to measure depression severity including suicidality Other clinician-reported outcomes include the Liebowitz Social Anxiety Scale (LSAS), the Panic Disorder Severity Scale (PDSS), the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), the Clinician Global Impression-Severity and Improvement Scales (CGI-S and CGI-I), and the Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER).
Principal Investigator
Dr. Viviënne van de Walle, MD, PHD
Dr. Van de Walle studied medicine both at the University of Maastricht – The Netherlands and at the University of Oxford - UK. In addition to her MD degree, she holds degrees in Genetics, Pediatrics, and Gynecology.
For more information on the Study Sponsor (Nubellum Research), visit www.nubellum.com on the Internet.